TY - JOUR. T1 - ICRF-159 (razoxane) in patients with advanced adenocarcinoma of the endometrium. A gynecologic oncologic group study. AU - Homesley, H. D.. AU - Blessing, J. A.. AU - Conroy, J.. AU - Hatch, K.. AU - DiSaia, P. J.. AU - Twiggs, L. B.. PY - 1986/1/1. Y1 - 1986/1/1. N2 - Twenty-seven patients with advanced adenocarcinoma of the endometrium were accessioned into this Phase II study evaluating the efficacy of ICRF-159 (razoxane) as second-line chemotherapy between February 1981 and September 1983. One patient was ineligible because of an undocumented primary. One patient was inevaluable because of concurrent use of adjunctive therapy and one patient had an inadequate trial. Twenty-four evaluable patients with measurable disease were given ICRF-159 orally at a starting dose of 1.5 g/m2 weekly until response could be determined. Grade 4 hematologic adverse effects were the only significant toxicity. There was no evidence of tumor response in any of the patients. Fourteen patients had ...

Anticancer bisdioxopiperazines, including ICRF-154, razoxane (Raz, ICRF-159) and ICRF-193, are a family of anticancer agents developed in the UK, especially targeting metastases of neoplasms. Two other bisdioxopiperazine derivatives, probimane (Pro) and MST-16, were synthesized at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. Cytotoxic activities and mechanisms of Raz (+)-steroisomer (ICRF-187, dexrazoxane), Pro and MST-16 against tumor cells were evaluated by MTT colorimetry, flow cytometry and karyotyping. Pro was cytotoxic to human tumor cell lines in vitro (IC50|50 μM for 48 h). Four human tumor cell lines (SCG-7901, K562, A549 and HL60) were susceptible to Pro at low inhibitory concentrations (IC50 values | 10 μM for 48 h). Although the IC50 against HeLa cell line of vincristine (VCR, 4.56 μM), doxorubicin (Dox, 1.12 μM) and 5-fluoruouracil (5-Fu, 0.232 μM) are lower than Pro (5.12 μM), ICRF-187 (129 μM) and MST-16 (26.4 μM), VCR, Dox and 5-Fu shows

Anticancer bisdioxopiperazines, including ICRF-154, razoxane (Raz, ICRF-159) and ICRF-193, are a family of anticancer agents developed in the UK, especially targeting metastases of neoplasms. Two other bisdioxopiperazine derivatives, probimane (Pro) and MST-16, were synthesized at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. Cytotoxic activities and mechanisms of Raz (+)-steroisomer (ICRF-187, dexrazoxane), Pro and MST-16 against tumor cells were evaluated by MTT colorimetry, flow cytometry and karyotyping. Pro was cytotoxic to human tumor cell lines in vitro (IC50|50 μM for 48 h). Four human tumor cell lines (SCG-7901, K562, A549 and HL60) were susceptible to Pro at low inhibitory concentrations (IC50 values | 10 μM for 48 h). Although the IC50 against HeLa cell line of vincristine (VCR, 4.56 μM), doxorubicin (Dox, 1.12 μM) and 5-fluoruouracil (5-Fu, 0.232 μM) are lower than Pro (5.12 μM), ICRF-187 (129 μM) and MST-16 (26.4 μM), VCR, Dox and 5-Fu shows

The pharmacokinetics of dexrazoxane have been studied in advanced cancer patients with normal renal and hepatic function. The pharmacokinetics of dexrazoxane can be adequately described by a two-compartment open model with first-order elimination. Dexrazoxane has been administered as a 15 minute infusion over a dose range of 60 to 900 mg/m2 with 60 mg/m2 of doxorubicin, and at a fixed dose of 500 mg/m2 with 50 mg/m2 doxorubicin. The disposition kinetics of dexrazoxane are dose-independent, as shown by linear relationship between the area under plasma concentration-time curves and administered doses ranging from 60 to 900 mg/m2. The mean peak plasma concentration of dexrazoxane was 36.5 µg/mL at 15- minute after intravenous administration of 500 mg/m2 dose of ZINECARD over 15 to 30 minutes prior to the 50 mg/m2 doxorubicin dose.. The important pharmacokinetic parameters of dexrazoxane are summarized in Table 2: ...

Trade Name: Zinecard®. For which conditions is this drug approved? Dexrazoxane is FDA approved for the prevention or reduction of severity of heart complications that can be caused by the chemotherapy agent doxorubicin. Patients have typically received high cumulative doses of doxorubicin prior to initiation of dexrazoxane. It is important for patients to remember that physicians have the ability to prescribe medication for conditions other than those for which the drug has been approved by the FDA. Patients who have received a prescription of this drug for a condition other than which it is approved may wish to discuss this issue with their physician.. What is the mechanism of action? Dexrazoxane is believed to protect the heart from damage caused by doxorubicin by interfering with the component of doxorubicin that is thought to damage the heart.. How is dexrazoxane typically given (administered)? Dexrazoxane is administered through a vein, prior to the administration of doxorubicin, and the ...

Background Randomized clinical trials showed the benefit of pharmacological and revascularization treatments in secondary prevention of myocardial infarction (MI), in selected population with highly controlled interventions. The objective of this study is to measure these treatments impact on the cardiovascular (CV) mortality rate among patients receiving usual care in the province of Quebec. Methods The study population consisted of a naturalistic cohort of all patients ? 65 years old living in the Quebec province, who survived a MI (ICD-9: 410) in 1998. The studied dependant variable was time to death from a CV disease. Independent variables were revascularization procedure and cardioprotective drugs. Death from a non CV disease was also studied for comparison. Revascularization procedure was defined as percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG). The exposure to cardioprotective drugs was defined as the number of cardioprotective drug classes

Dexrazoxane hydrochloride (Zinecard by Pfizer in USA and Canada; Cardioxane by Clinigen Group for EU and other countries) is a cardioprotective agent. It was discovered by Kurt Hellmann in 1972. Dexrazoxane is a sterile, pyrogen-free lyophilizate intended for intravenous administration. The IV administration of dexrazoxane is in acidic condition with HCl adjusting the pH. Dexrazoxane has been used to protect the heart against the cardiotoxic side effects of chemotherapeutic drugs such as anthracyclines, such as daunorubicin or doxorubicin or other chemotherapeutic agents. However, in July 2011 the US Food and Drug Administration released a statement restricting use only in adult patients with cancer who have received > 300 mg/m2 doxorubicin (an anthracycline) or > 540 mg/m2 epirubicin (another chemotherapeutic agent) and general approval for use for cardioprotection. That showed a possibly higher rate of secondary malignancies and acute myelogenous leukemia in pediatric patients treated for ...

Dexrazoxane is used to protect the heart and other tissues from harmful side effects caused by certain cancer medications. The Zinecard brand of dexrazoxane is used in women who are receiving doxorubicin for metastatic breast cancer. The Totect brand of dexrazoxane is used in men or women to treat a condition called...

Objective We investigated the impact of cardioprotective drugs on ST-elevation, arrhythmias and infarct size in a rat model of repetitive coronary artery occlusion. alone and RO plus nitroglycerin were associated with significantly lower maximal ST-elevation and percentage of infarcted myocardium (SHAM 0.12 mV, 741713-40-6 ROP 0.06 mV (p=0.004), NTG 0.05 mV (p=0.005); SHAM 16.2%, ROP 6.6% (p=0.008), NTG 5.9% (p=0.006). Compared with RO alone, RO plus RAN was accompanied by increased ST-elevation (0.13 mV, p=0.018) and RO plusVER or CAN by more infarcted myocardium (14.2%, p=0.004% and 15.5%, p=0.003, respectively). Rats treated with VER, RAN or CAN tended to severe arrhythmias more frequently than those of the control groups. Conclusions RO led to an increased myocardial resistance against ischaemia 741713-40-6 and reperfusion injury. Concomitant administration of nitroglycerin didnt affect the efficiency of RO. Cardiovascular receptor or route blockers decreased the efficacy of RO. discovered ...

During the initial operation of the International Thermonuclear Experimental Reactor (ITER), it is envisaged that activation will be minimized by using hydrogen (H) plasmas where the reference ion cyclotron resonance frequency (ICRF) heating scenarios rely on minority species such as helium (He-3) or deuterium (D). This paper firstly describes experiments dedicated to the study of He-3 heating in H plasmas with a sequence of discharges in which 5 MW of ICRF power was reliably coupled and the He-3 concentration, controlled in real-time, was varied from below 1% up to 10%. The minority heating (MH) regime was observed at low concentrations (up to 2%). Energetic tails in the He-3 ion distributions were observed with effective temperatures up to 300 keV and bulk electron temperatures up to 6 keV. At around 2%, a sudden transition was reproducibly observed to the mode conversion regime, in which the ICRF fast wave couples to short wavelength modes, leading to efficient direct electron heating and ...

Topoisomerase II is an ATP-operated protein clamp that captures a DNA helix and transports it through another DNA duplex, allowing chromosome segregation at mitosis. A number of cytotoxic bisdioxopiperazines such as ICRF-193 target topoisomerase II by binding and trapping the closed enzyme clamp. To investigate this unusual mode of action, we have used yeast to select plasmid-borne human topoisomerase IIα alleles resistant to ICRF-193. Mutations in topoisomerase IIα of Leu-169 to Phe (L169F) (in the N-terminal ATPase domain) and Ala-648 to Pro (A648P) (in the core domain) were identified as conferring ,50-fold and 5-fold resistance to ICRF-193 in vivo, respectively. The L169F mutation, located next to the Walker A box ATP-binding sequence, resulted in a mutant enzyme displaying ICRF-193-resistant topoisomerase and ATPase activities and whose closed clamp was refractory to ICRF-193-mediated trapping as an annulus on closed circular DNA. These data imply that the mutation interferes directly ...

Dexrazoxane(Zinecard) generic is a cardioprotective agent, prescribed for reducing the risk of heart damage from doxorubicin, an anticancer medication. It works by stopping the chemotherapy medications from damaging the heart and the tissues.

Dexrazoxane (Zinecard) side effects, how its given, how it works, precautions and self care tips as a chemoprotectant in treatment of metastatic breast cancer

ZINECARD (Dexrazoxane) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.

Safi , E , Polvi , J H , Lasa Esquisabel , A & Nordlund , K H 2016 , Atomistic Simulations Of Deuterium Irradiation On Iron-based Alloys In Future Fusion Reactors Nuclear materials and energy , vol. 9 , pp. 571-575 . DOI: 10.1016/j.nme.2016.08.021. ...

Development of sustainable catalytic systems for fundamentally important synthetic transformations and energy storage applications is an intellectually stimulating challenge. Catalytic dehydrogenation of feedstock chemicals, such as alcohols and amines to value-added products with the concomitant generation of dihydrogen is of much interest in the context of hydrogen economy and is an effective alternative to the classical oxidation reactions. Despite a number of homogeneous catalysts being identified for the acceptorless dehydrogenation, the use of high price and limited availability of precious metals and poor recovery of the catalyst have spurred interest in catalysis with more earth-abundant alternatives, especially iron. However, no report has described a reusable iron-based heterogeneous catalyst for oxidant-free and acceptorless dehydrogenation reactions. Here we replace expensive noble metal catalysts with an inexpensive, benign, and sustainable nanoscale iron catalyst for the efficient

An investigational iron-based phosphate binder is effective and well tolerated in hemodialysis (HD) patients with hyperphosphatemia.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.. Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.. ...

This project extends previously discovered Fe-based catalysts to hydrogen-poor synthesis gas streams derived from coal and biomass sources. These catalysts have shown unprecedented Fischer-Tropsch synthesis rate, selectivity for feedstocks consisting of synthesis gas derived from methane. During the first reporting period, we certified a microreactor, installed required analytical equipment, and reproduced synthetic protocols and catalytic results previously reported. During the second reporting period, we prepared several Fe-based compositions for Fischer-Tropsch synthesis and tested the effects of product recycle under both subcritical and supercritical conditions. During the third and fourth reporting periods, we improved the catalysts preparation method, which led to Fe-based FT catalysts with the highest FTS reaction rates and selectivities so far reported, a finding that allowed their operation at lower temperatures and pressures with high selectivity to desired products (C{sub 5+}, olefins).

Permeable Reactive Barriers (PRBs) are a promising, though still relatively new approach to remediating groundwater contaminated with heavy metals or organics. However, there is still uncertainty about the longevity of these passive, in situ systems. This research aims to improve this technology by contributing to understanding of their geochemical performance and by extending their operational longevity.. To gain a fundamental understanding of the hydraulic changes in reduced metal media in the subsurface. Based on this mechanistic understanding, this research will aim to extend the longevity of PRBs by manipulating the particle size distribution of the reactive media, as well as the ratio of reactive to non-reactive media.. ...

OVENTROP-DZR brass balancing valve Hycocon APZ without presetting, both ports press connection, -10 °C up to +120 °C, oblique pattern. Valve body, bonnet...

(2017) Iimura et al. Journal of Asian Ceramic Societies. We report the single crystal growth and characterization of the highest T c iron-based superconductor SmFeAsO 1−x H x . Some sub-millimeter-sized crystals were grown using the mixture flux of Na 3 As + 3NaH + As at 3.0 GPa and 1473 K. The c...

Bio-inspired iron-based catalyst for producing hydrogen. Key atoms and groups are indicated. The color convention throughout is Fe atoms, brown; S atoms,

Iron-bacteria is a nuisance bacteria. It is not a health hazard. It is a iron-based slime that can grow in pipes, on filters, etc. and reduce water flow. It can also ...

Order online at Screwfix.com. Chrome-plated DZR brass construction. Suitable for water. NHS DO8 model engineering specification. FREE next day delivery available, free collection in 5 minutes.

Id be really cautious of building anything beneath your oak tree. Changing the soil level can kill the roots, as can planting anything beneath it. Im afraid the best solution is to rake up or vacuum up the acorns in the fall when most of them have dropped. You might be able to install weed barrier landscape fabric under the canopy of the tree to stop acorns from sprouting or at least from rooting in the soil. You can top the weed barrier with an inch or two of bark to disguise it. Weed barrier fabric has tiny holes that allow moisture to trickle through but blocks sunlight so seeds wont sprout. Hope it works for you ...

University of Michigan Hospitals and Health Center procedure pricing information for a CT Angiography - Neck can be found listed below. Find a cost comparison to other providers in Ann Arbor, MI and see your potential savings.

Objective- Dexrazoxane is an antioxidant prodrug that on hydrolysis is converted into an intracellular iron chelator. We hypothesized that the antioxidant effects of dexrazoxane would prevent homocysteine-induced endothelial dysfunction in the brachial artery of normal human subjects.. Methods and Results- Ten healthy volunteers completed a randomized, double-blind, crossover study. Plasma homocysteine levels and brachial artery endothelium-dependent (flow-mediated dilation [FMD]) and endothelium-independent (sublingual nitroglycerin) responses were measured before and 4 hours after ingestion of l-methionine (100 mg/kg), preceded by intravenous administration of dexrazoxane (500 mg/m2) or placebo over 30 minutes. After placebo, oral methionine increased plasma homocysteine (from 5.1±0.4 μmol/L at baseline to 14.2±1.3 μmol/L at 4 hours, P,0.001) and decreased FMD (from 3.8±0.7% at baseline to 1.2±0.5% at 4 hours, P=0.02). Dexrazoxane did not change homocysteine concentrations after ...

Zinecard For Injection - intravenous (1 vial) Zinecard For Injection With Sodium Lactate Injection - other, intravenous (1) Zinecard For Injection With Sodium Lactate Kit - other, intravenous (1) - Razoxane (Dexrazoxane), Sodium Lactate ...

Title: The Central Sympathetic Nervous System: A New Target for Cardioprotective Drugs. VOLUME: 2 ISSUE: 4. Author(s):E. Tibirica and M. A. Lessa. Affiliation:Departamento de Fisiologia e Farmacodinamica, Instituto Oswaldo Cruz, FIOCRUZ, Av. Brasil 4365 -Manguinhos, C. P. 926, 21045-900, Rio de Janeiro, RJ, Brazil.. Keywords:cardioprotection, sympathetic overactivity, centrally acting antihypertensive drugs, opioids, myocardial ischemia. Abstract: Activation of the central sympathetic nervous system has proved to be a definitive pathophysiological feature in cardiovascular diseases such as primary arterial hypertension, heart failure and arrhythmogenesis during myocardial ischemia. In fact, experimental and clinical evidence suggests sudden cardiac death in ischemic patients to be, at least in part, mediated by the central sympathetic nervous system. In addition to the use of peripherally acting sympatholytic agents, sympathetic overactivity can also be modulated by drugs acting directly on its ...

Anthracyclines are among the most effective chemotherapy treatments available for various types of cancer. However, there is a risk of damage to the heart (cardiotoxicity) depending on the cumulative dose. Certain drugs might prevent this damage, but for many of these drugs, the review authors found no high quality evidence about whether they were effective in protecting the heart and they were unable to draw conclusions. For dexrazoxane, the review authors found 10 studies enrolling over 1600 patients. These studies provided evidence that dexrazoxane prevented heart damage without interfering with the anti-tumour effects of anthracycline treatment. Patients who got dexrazoxane with their anthracycline treatment had about one third of the risk of heart failure compared to patients who got anthracyclines without dexrazoxane. Dexrazoxane had no effect on survival. We cant be sure about whether it had any undesirable side effects.. ...

Kim, H., Shakoor, R. A., Park, C., Lim, S. Y., Kim, J.-S., Jo, Y. N., Cho, W., Miyasaka, K., Kahraman, R., Jung, Y. and Choi, J. W. (2013), Na2FeP2O7 as a Promising Iron-Based Pyrophosphate Cathode for Sodium Rechargeable Batteries: A Combined Experimental and Theoretical Study. Adv. Funct. Mater., 23: 1147-1155. doi: 10.1002/adfm.201201589 ...

Read Effect of Phosphorus on Microstructure and Mechanical Properties of Iron-Based Alloys Processed Through Powder Forging, Metallography, Microstructure, and Analysis on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.

In this large retrospective analysis of 111,847 patients in the CRUSADE initiative, approximately 36% were overweight and approximately 35% were obese. Extremely obese patients (BMI ,40 kg/m2, approximately 6% of the sample) experienced their first MI on average approximately 16 years earlier than their lean counterparts. After adjustment for potential confounders, the age differential remained substantial at approximately 12 years. Although there were higher rates of almost all cardiovascular risk factors in the obese patients, these were countered with higher rates of prescribed cardioprotective drugs at baseline. A previous CRUSADE study confirmed higher rates of risk factors and prescribed cardioprotective drugs in this patient subset. The investigators reported that obese individuals received more aggressive coronary management, which was associated with improved outcomes (12).. Our multivariate analysis confirmed that higher BMI reduced the age of first NSTEMI more than any other variable, ...

The ability of ZINECARD to prevent/reduce the incidence and severity of doxorubicin-induced cardiomyopathy was evaluated in three prospectively randomized placebo-controlled studies. In these studies, patients were treated with a doxorubicin-containing regimen and either ZINECARD or placebo starting with the first course of chemotherapy. There was no restriction on the cumulative dose of doxorubicin. Cardiac function was assessed by measurement of the LVEF, utilizing resting multigated nuclear medicine (MUGA) scans, and by clinical evaluations. Patients receiving ZINECARD had significantly smaller mean decreases from baseline in LVEF and lower incidences of congestive heart failure than the control group; however, in the largest study, patients with advanced breast cancer receiving FAC with ZINECARD had a lower response rate (48% vs. 63%) and a shorter time to progression than patients who received FAC versus placebo.. In the clinical trials, patients who were initially randomized to receive ...

Extravasations (EV) of anthracyclines (AC) are a rare but potentially seriously debilitating complication of chemotherapies (CT) that can lead to severe skin lesions with the need for surgical debridement, a functional disability in the short and longer term, and a delay in the CT programme following on from EV management.. Savene is the only antidote authorised for the treatment of AC EVs. The treatment involves a peripheral intravenous infusion lasting 1 to 2 hours, to be started as soon as possible and within 6 hours following the EV, to be repeated 24 hours and 48 hours after the 1st infusion. The treatments effectiveness was first demonstrated during clinical testing on peripheral EVs, confirmed by biopsy, with a rate of 98% of being able to dispense with the need for surgery due to ulceration or tissue necrosis, and the initial CT programme being maintained in 71% of patients. These efficacy data were recently confirmed in Belgium, in clinical practice, with 41 patients showing an AC EV, ...

1.Sánchez G, Cervantes G y Maldonado J. Linfomas No Hodgkin. Med Int Mex 2004; 20: 111-23. 2.Estrada D, Rajdev L and Sparado J. Lymphoma, Non-Hodgkin. Emedicine. Last Updated: June 24, 2004. 3.Ng R, Better N, Green MD. Anticancer agents and cardiotoxicity. Semin Oncol. 2006; 33 (1): 2-14. 4.Youssef G, Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs. 2005; 5 (4): 233-43. 5.Pasca A, Pereiro G, Mansilla S y Lastiri H. Toxicidad miocardiaca por antraciclinas. Rev Fed Arg Cardiol 2000; 29:319-325. 6.Suter T and Meier B. Detection of anthracycline- induced cardiotoxicity: is there light at the end of the tunnel?. Editorial. Annals of Oncology. 2002; 13: 647-649. 7.Cvetkovic RS, Scott LJ. Dexrazoxane a review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005; 65 (7): 1005-24. 8.Gianni L, Haerman E, Lipshultz S, Minotti G, sarvazyan N and Sawyer D.Anthracycline Cardiotoxicity: From Bench ...

Among patients who have relapsed or have experienced a subsequent malignancy other than non-melanomatous skin cancer since their original diagnosis, the study committee will review the available data (both from Childrens Oncology Groups [COGs] Statistics and Data Center [SDC] and the participating institution) to determine if individual patients are to be selected for Stratum 2; in recognition that local institutions sometimes have more updated relapse/subsequent cancer data than SDC, in cases where local data is more updated, local data will be used preferentially; the study will petition the Institutional Review Board (IRB) specifically for a waiver of consent to include any relapse and subsequent cancer data obtained from existing records for analysis of the secondary aims; patients selected for Stratum 2 will be those for whom late relapse or subsequent cancer is reported but who lack clear confirmation in existing records (either at SDC or at the local institution ...

Supplementary Materialscancers-12-00223-s001. cell proliferation, and reduces apoptosis and epithelial differentiation. MAGI1 downregulation in the ER+ murine BC cell collection 67NR accelerates main tumor growth and enhances experimental lung metastasis formation. MAGI1 expression is definitely upregulated by estrogen/ER, downregulated by prostaglandin E2/COX-2axis, and negatively correlates with swelling in ER+/HER2? BC patients. Taken together, we display that MAGI1 is definitely a new potential tumor suppressor in ER+/HER2? breast cancer with possible prognostic value for the recognition of individuals at high-risk of relapse within this subset. = 12 tumors). (d) Dexrazoxane HCl Western blot showing MAGI1 and ER protein Dexrazoxane HCl levels in MCF7 (ER+/HER2?), BT474 (HER2+), and MDA-MB-231 (basal-like, ER?/HER2?) cell lines. GAPDH is used as loading control. Band intensity ratio modified to GAPDH is definitely shown next to the blot. These results indicate that in BC, MAGI1 expression is ...

A method is disclosed for detecting the occurrence of a binding or complex-forming reaction between specific substances by utilizing the binding reaction to modify an electrical circuit, and then measuring a change in the electrical state of the circuit. A diagnostic element (1D) useful in such a method includes a layer of a biogenic substance (30A), such as an antigenic (12A), coated onto a non-conductive base (22A) between a pair of electrical conductors (23A, 24A) superposed on the base (22A). Electrically conductive, metallic particles (14A) having antibody (15A) which reacts with the antigen (12A) bound thereto (15A), are added to the antigen layer (30A) deposited on the base (22A) and allowed to react therewith. Electrically conductive particles (14A) are thereby bound to the base (22A) due to the binding reaction between the antigen (12A) and antibody (15A) to thereby form aggregates (35A) of electrically conductive particles (14A) which modify the circuit.

Triazene ligands are introduced, for the first time, in the precursor chemistry for their ability to afford oxygen-free molecular precursors of Fe0 nanoparticles. For this purpose, we synthesized new asymmetric triazene ligands t-BuN [[double bond, length as m-dash]] N-NHR (R = Et, i-Pr, n-Bu) featuring differe...

Dental caries is a global risk of oral health for many schoolchildren and vast majority of adults. The primary factor for caries formation is that bacteria attach on tooth surface to form an oral biofilm which generates acids to demineralize calcium and eventually cause tooth decay. It is still challenging f Biomimetic Therapeutics

Over the last 40 years, a significant advance has been made in the treatment of childhood and adult cancers. However, the increase of the survival rate points out medium- and long-term adverse effects that constitute a serious limitation for the quality of life in adults survived from a childhood ca …

Mouse monoclonal antibody raised against native ITGAM. Native purified ITGAM from rheumatoid synovial cells and human monocytes. (MAB6032) - Products - Abnova

Integrins are heterodimeric cell surface receptors composed of alpha and beta subunits, which mediate cell-cell and cell-extracellular matrix attachments. Aberrant

Iron In The Mix - Science News: In a paper published in Physical Review Letters in 2008, Singh and three other colleagues, including theorist Igor Mazin of the U.S. Naval Research Laboratory in Washington, D.C., suggested that pairing in iron-based superconductors is closer to pairing in cuprates than to that of traditional superconductors, yet is still different. Electrons maintain their distance, but there are no specific traveling directions that will break pairs apart. Such pairing differences could mean that the mechanism of superconductivity is not the same in the two families ...

The discoverer of the first iron-based superconductor, one of Science magazines 2008 runner-up breakthroughs of the year, now reports finding around 100 new superconducting materials.

Choi, C. H.; Lim, H.-K.; Chung, M. W.; Chon, G.; Ranjbar Sahraie, N.; Altin, A.; Sougrati, M. T.; Stievano, L.; Oh, H. S.; Park, E. S. et al.; Strasser, P.; Dražić, G.; Mayrhofer, K. J. J.; Kim, H.; Jaouen, F.: The Achilles heel of iron-based catalysts during oxygen reduction in an acidic medium. Energy & Environmental Science 11 (11), pp. 3176 - 3182 (2018 ...

The KAAP process is a more efficient ammonia process technology; the catalyst used is 20 times more active than traditional iron-based catalysts.

The wide spectrum of anthracycline activity as well as the unique cumulative dose related cardiac toxicity pose a significant clinical challenge. These drugs, particularly doxorubicin (AdriamycinR),...

Hello Shane, Its Mike here. Found your post on the Internet Immunology group. I think the answer you are looking for is Hidde Ploeghs HC-10 MoAb. He is usually very good about giving it out and there is a stock at the ICRF. He also uses a rabbit polyclonal serum to do the same job. In the original Stam paper they never actually say how the stuff was raised but I suspect it has something to do with SDS extracts since you can immunoprecipitate these with it. If you need more help get in touch. Mike Whelan IAH ...

Metodický materiál pro Středisko prevence úrazů v Jihočeském kraji IGA MZ ČR NR /2005 PREVENCE ÚRAZŮ, OTRAV A NÁSILÍ Časopis je určen všem zařízením, která se zabývají prevencí úrazů, krizovým centrům,

Fifty 件の 2021 のベスト Raz ポッドキャスト. 最新のエピソードは Ewangelia św Jana rozdział 5 wersety 1-6 になった。. オンラインで聴いて、サインアップは必要ありません。.

Forex charts by esignal #### TUNNELING METHOD OF FOREX TRADING Rating Forex trading robots bribyl′nyh #### Quiet time in the Forex market